Influence of Diabetes and Type of Hypertension on Response to Antihypertensive Treatment
- 1 May 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 35 (5) , 1038-1042
- https://doi.org/10.1161/01.hyp.35.5.1038
Abstract
Abstract —The aim of our investigation was to determine whether the presence of additional risk factors or type of hypertension (diastolic or isolated systolic) influences blood pressure (BP) response to treatment. The International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) study is a double-blinded outcome comparison of calcium channel blockade with diuretics in high-risk patients aged 55 to 80 years. Dynamic randomization between nifedipine once daily and hydrochlorothiazide/amiloride was performed to ensure that approximately equal numbers of patients in the 2 groups had each of the major cardiovascular risk factors. Patients with isolated systolic hypertension were also separately randomized. Atenolol or enalapril was the mandatory second-line drug. In 5669 patients who completed the 18-week titration, BP fell from 172±15/99±9 mm Hg (mean±SD) while receiving placebo to 139±12/82±7 mm Hg. Twenty-six percent of patients required 2 drugs, and 4% required 3 drugs. Patients with diabetes were the most resistant to treatment, requiring second and third drugs 40% and 100% more frequently than patients without diabetes and achieving marginally the highest final BP, for any risk group, of 141±13/82±8 mm Hg. Age, smoking, gender, hypercholesterolemia, left ventricular hypertrophy, and existing atherosclerosis had little (<1 mm Hg) or no influence on BP at the end of titration, but all except smoking slightly reduced the initial response of either systolic or diastolic BP. Patients with isolated systolic hypertension were slightly more responsive than average to treatment. Our findings suggest that in patients at high absolute risk of cardiovascular complications from hypertension, the risk factors themselves do not prevent the recommended BP targets from being achieved.Keywords
This publication has 13 references indexed in Scilit:
- Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialThe Lancet, 1999
- Minimisation: the platinum standard for trials?BMJ, 1998
- Survival in treated hypertension: follow up study after two decadesBMJ, 1998
- Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatmentJournal Of Hypertension, 1998
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998
- Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 1997
- Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE studyBMJ, 1997
- Dynamic balanced randomization for clinical trialsStatistics in Medicine, 1993
- Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with PlaceboNew England Journal of Medicine, 1993
- Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.BMJ, 1992